Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19689519 | 1.00 | ACHE (0.36) | ACHECYP1A2CYP3A4CYP2C19EPAS1 | |
| SCHEMBL22772572 | 1.00 | ACHE (0.36) | ACHECYP1A2CYP3A4CYP2C19EPAS1 | |
| SCHEMBL19216538 | 0.81 | ALDH1A1 (0.42) | ACHECYP3A4CA12CA1CA2 | |
| SCHEMBL28153812 | 0.81 | ALDH1A1 (0.42) | ACHECYP3A4CA12CA1CA2 | |
| SCHEMBL20150887 | 0.77 | ALDH1A1 (0.34) | CYP3A4EPAS1CA12CA1CA2 | |
| SCHEMBL20148158 | 0.77 | ALDH1A1 (0.34) | CYP3A4EPAS1CA12CA1CA2 | |
| SCHEMBL30995251 | 0.76 | ACHE (0.38) | ACHEEPAS1CA12CA1CA9 | |
| SCHEMBL28403114 | 0.76 | ACHE (0.38) | ACHEEPAS1CA12CA1CA9 | |
| Hydrochloric Acid SCHEMBL28407167 | 0.74 | ACHE (0.37) | ACHEEPAS1CA12CA1CA9 | |
| SCHEMBL30975537 | 0.74 | MAPT (0.33) | ACHEEPAS1CA1CA2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4691553-A2 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4534536-A1 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| US-20250026744-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2025-01-23 | — | — | US | disclosed |
| EP-3746448-B1 | NITROGENOUS TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2025-01-15 | — | — | EP | disclosed |
| CN-113302190-B | FXR (NR 1H 4) modulating compounds | 吉利德科学公司 | 2024-10-18 | — | — | CN | disclosed |
| EP-4089072-B1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2024-08-28 | — | — | EP | disclosed |
| EP-4360632-A2 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-117924266-A | Compounds that modulate FXR (NR 1H 4) | 吉利德科学公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117924267-A | Compounds that modulate FXR (NR 1H 4) | 吉利德科学公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-109476636-B | Compounds that modulate FXR (NR 1H 4) | 吉利德科学公司 | 2024-01-09 | — | — | CN | disclosed |
| US-20200255418-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2020-08-13 | — | — | US | disclosed |
| WO-2020150136-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20200071282-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2020-03-05 | — | — | US | disclosed |
| US-20190308962-A1 | FXR (NR1H4) Modulating Compounds | GILEAD SCIENCES, INC. (US) | 2019-10-10 | — | — | US | disclosed |
| US-10421730-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2019-09-24 | — | — | US | disclosed |
| EP-3257847-B1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2019-08-21 | — | — | EP | disclosed |
| CN-110128432-A | Tricyclic nitrogen containing compounds and its application in drug | 广东东阳光药业有限公司 | 2019-08-16 | — | — | CN | disclosed |
| WO-2017218330-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2017-12-21 | — | — | WO | disclosed |
| EP-3257847-A1 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308962-A1 | FXR (NR1H4) Modulating Compounds | NR1H4, NR1H2, NR1H3 | ACHE 4777/4885CYP1A2 1291/4885CYP3A4 744/4885 |
| US-20250026744-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | ACHE 4852/4885CYP1A2 2063/4885CYP3A4 1441/4885 |
| US-10421730-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | ACHE 4808/4885CYP1A2 1763/4885CYP3A4 1126/4885 |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | ACHE 4808/4885CYP1A2 1763/4885CYP3A4 1126/4885 |
| US-20200071282-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | ACHE 4808/4885CYP1A2 1763/4885CYP3A4 1126/4885 |
| US-20200255418-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | ACHE 4852/4885CYP1A2 2063/4885CYP3A4 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.